Fulgent Genetics

Breast Cancer Awareness Month campaigns run throughout October, but we know the work runs year-round: patients navigating a new diagnosis, families asking what a result means for their own risk, and the genetic counselors, oncologists, and lab teams who sit with those questions every day.

We're grateful to be part of that work, and grateful to the advocates, researchers, and clinicians who keep pushing it forward. Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us — and this month is a good reminder of what that means and who it impacts.

If breast cancer runs in your family, talk with your doctor or a genetic counselor about whether genetic testing could be useful for you.

Fulgent Genetics is heading to MDS Congress 2026 in Seoul, South Korea from Oct 4–8! Visit us at Booth #182 to learn how our genetic testing solutions & multiomics support the Parkinson's and rare movement disorder community.

We're proud to support advancing research in this space through our contribution to a poster presented by the Parkinson's Foundation's PD GENEration program:

“Evaluating the GBA1 Intronic rs3115534-G PD Risk Variant in the PD GENEration Cohort”

At our booth, our team will be on hand to discuss:

🔸 BioPharma services supporting biomarker discovery, companion diagnostic development, and clinical trial genomics for movement disorder drug programs.

🔸 Custom and NGS panels to support patient stratification and target identification in neurogenetic trials.

🔸 Whole Exome and Whole Genome Sequencing at scale, including FulgentExome (CE-IVD), for clinical applications.

🔸 Whole Genome Sequencing powered by Illumina TruPath for detecting repeat-expansion and structural variants relevant to neurodegenerative mechanisms.

🔸 Fulgent RISE - pairing WES/WGS with RNA sequencing to add transcriptomic insight for biomarker and mechanism-of-action studies.

We look forward to connecting with you!

Booth #182 | MDS Congress 2026 | Oct 4–8

FulgentExome carries CE-IVD marking for clinical use where applicable. Other sequencing and testing services described are offered for research use and/or as laboratory developed tests, as applicable to each service.

Fulgent now offers RFC1 repeat expansion analysis using a two-step approach, built for expansions that can exceed the range conventional repeat-expansion PCR is designed to cover.

An initial allele-check PCR resolves samples with alleles in the normal size range. Samples not resolved at that step move to long-read sequencing, which characterizes both the motif pattern and the size of the expansion. The assay analyzes for pathogenic expanded motifs (≥250 AAGGG and ≥600 AAAGG) that fall into a range where conventional approaches often reach their limit.

Results are reported as positive for two common expanded alleles, or negative for zero to one expanded allele.

See the full test details: https://www.fulgentgenetics.com/rfc1-repeat-expansion

RFC1 repeat expansion analysis is available through your healthcare provider. This is a laboratory developed test, developed and validated by Fulgent Therapeutics LLC and performed in our CLIA-certified, CAP-accredited laboratory. This test has not been cleared or approved by the FDA.

Fulgent Genetics is joining the Epic Aura network in Q4 2026.

Epic Aura connects performing labs like Fulgent to provider organizations using Epic. We're excited to share that soon, clinicians at connected organizations will be able to order Fulgent testing and receive results in the workflow they already use.

Learn more at the Epic Showroom now: https://showroom.epic.com/Listing?id=3661&returnTitle=6



Epic, Aura, and Epic Showroom are trademarks of Epic Systems Corporation.

Last month, our skeletal dysplasia panel grew by 188 genes, while our vascular malformation panel added 29.

Our team is constantly working to ensure our panels are up to date, because a gene that wasn't included last month may now be the one that explains a patient's phenotype and provides the answers they seek.

As with most Fulgent tests, each panel can be tailored to a focused subset of genes to fit the clinical needs of individual patients.

Has broader panel coverage ever changed the path to a diagnosis for one of your patients? We'd like to hear how it played out.

Explore our heritable disease panel menu at https://fulgentgenetics.com/products/disease/raredisease.html

18,000+ single gene tests. 900+ panel tests. One lab.

Reproductive health, oncology, rare disease, pharmacogenomics, anatomic pathology — our menu spans a lot of ground. Providers and institutions shouldn't have to juggle multiple labs to get a full picture of a patient's care.

If you could ask for one new panel or test to be added to a lab's menu, what would it be?

Our team's contributions to the field of genomics take a lot of forms — peer-reviewed publications, conference posters, presentations, even podcast appearances.

Case in point: Jay Shaw, MS, CGC, spoke with Progyny last year on their "This is Infertility" podcast. In her episode ("Fertility 101: The Basics of Genetics and Genetic Testing"), she explores how genetic testing informs fertility care, IVF, and pregnancy planning.

You can find this episode link, along with the rest of our team's published and presented work, on our Publications page: https://web.fulgentgenetics.com/resources/publications

What kind of content — papers, talks, podcasts — do you find most useful for staying current in the field?

Ever wondered how we approach a variant reclassification, or when segregation testing might be recommended?

Our testing policies — including our variant reclassification policy, segregation testing policy, and exome/genome reanalysis policy — are all available for clinicians and genetic counselors to reference directly.

Visit our testing policies page: https://web.fulgentgenetics.com/resources/testing-policies

What's a policy or process that you wish were easier to find or understand?

Fulgent is care.

Behind every report is a team that takes the relationship seriously — with clinicians who call us with questions, and patients navigating results that matter to their lives. We're proud of the relationships we've built.

What's made a lab feel like a true partner to you, rather than just a vendor?

Fulgent is quality.

Our genomic panels and proprietary pipelines are built by leaders in the field. As a CLIA-certified, CAP-accredited lab, quality is built into our procedures at every step, with multiple lab directors overseeing clinical analysis.

What does quality look like to you when you're evaluating a lab partner?